These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 12647196)

  • 21. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.
    Nuijten MJ; Wittenberg W; Lebmeier M
    Pharmacoeconomics; 2007; 25(1):55-71. PubMed ID: 17192118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.
    Parnes C; Guillermin J; Habersang R; Nicholes P; Chawla V; Kelly T; Fishbein J; McRae P; Goessler M; Gatti A; Calcagno JA; Eki C; Harris KA; Joyave J; McFarland K; Protter P; Sullivan M; Stanford A; Lovett N; Ortiz M; Rojas S; Cyrus S; Cyrus J; Cohen S; Buchin D; Riordan L; Zuniga M; Shah R; Minard C; Quintin A; Douglas G; van Houten J; Freutner S; Chartrand S; Nowatzke P; Romero J; Rhodes T; Benoit M; Walter E; Walker L; DeBonnett L; Cross M; Free T; Martin S; Shank K; Guedes B; Atkinson LA; Halpin GJ; Rouse K; Hand I; Geiss D; Marshall JR; Burleson L; Boland J; Seybold K; Hunter V; Unfer S; Schmucker J; Gley M; Marcus M; Thompson P; Milla P; Young C; Zanni R; Zinno V; Fetter-Zarzeka A; Busey A; Sokunbi MA; Airington S; Richard N; Muraligopal V; Lewis S; Weber FT; Giordano BP; Linehan D; Roach J; Davis R; Rzepka AA; Booth T; Smeltzer D; Walsh J; Arispe E; Rowley R; Bolling C; Botts T; Haskett K; Raby D; Batiz E; Gelfand A; Farrell L; Butler S; Colby L; Schochet P; Bentler J; Hirsch D; Wilkinson L; Aaronson A; Bennett E; Wingate J; Quinn D; Komendowski K; Deckard M; Frogel M; Nerwen C; Copenhaver S; Prater M; Wolsztein J; Mackey K; Benbow M; Naranjo M; Hensley S; Hayes C; Sadeghi H; Lawson SM; McCall M; Combs K; Ledbetter J; Sarnosky K; Swafford C; Speer M; Barton WJ; Mink JW; Lemm D; Hudak M; Case E; Rowen J; Fuentes S; Pane C; Richardson L; Chavarria C; Cassino D; Ghaffari K; Carroll C; Lee H; Guclu L; Johnson C; Blum V; Boron ML; Sorrentino M; Hirsch RL; Van Veldhuisen PC; Smith C;
    Pediatr Pulmonol; 2003 Jun; 35(6):484-9. PubMed ID: 12746948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
    Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
    J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
    Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
    Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
    BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
    Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
    J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
    Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
    An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cost-benefit analysis of RSV prophylaxis in high-risk infants.
    Schrand LM; Elliott JM; Ross MB; Bell EF; Mutnick AH
    Ann Pharmacother; 2001 Oct; 35(10):1186-93. PubMed ID: 11675842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health economics and RSV.
    Carbonell-Estrany X; Lázaro y de Mercado P
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A; Bruu AL
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.